Bayer joins Sensyne Health consortium for accelerating new medicine discovery

Sensyne Health and Bayer have announced that Bayer is to become Sensyne Health’s preferred pharmaceutical partner to work together on the development of a national linked patient data capability. Microsoft, EY, JP Morgan, and Peel Hunt are already in the consortium. Under the terms of the agreement, Bayer will work with Sensyne Health and the consortium members as they develop proposals to scale Sensyne Health’s current network of strategic research agreements with NHS Trusts, aiming to accelerate the discovery and development of new medicines and improve patient care through the analysis of large databases of anonymised patient data, using clinical artificial intelligence. Sensyne Health and its consortia of experts have the requisite capabilities in clinical AI, computing, data analytics, systems integration, business planning, investment banking and, with the addition of Bayer, the relevant pharmaceutical R&D expertise and capability.

Spotlight

Spotlight

Related News